Compare ADMA & PTY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ADMA | PTY |
|---|---|---|
| Founded | 2004 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.4B | 2.5B |
| IPO Year | 2012 | 2002 |
| Metric | ADMA | PTY |
|---|---|---|
| Price | $10.69 | $12.09 |
| Analyst Decision | Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $28.00 | N/A |
| AVG Volume (30 Days) | ★ 9.5M | 1.3M |
| Earning Date | 05-06-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.60 | N/A |
| Revenue | ★ $42,219,783.00 | N/A |
| Revenue This Year | $27.46 | N/A |
| Revenue Next Year | $22.11 | N/A |
| P/E Ratio | $17.49 | ★ N/A |
| Revenue Growth | ★ 43.85 | N/A |
| 52 Week Low | $7.21 | $11.58 |
| 52 Week High | $25.67 | $14.69 |
| Indicator | ADMA | PTY |
|---|---|---|
| Relative Strength Index (RSI) | 42.02 | 44.14 |
| Support Level | $7.21 | N/A |
| Resistance Level | $16.30 | $13.21 |
| Average True Range (ATR) | 0.61 | 0.15 |
| MACD | 0.29 | 0.04 |
| Stochastic Oscillator | 97.74 | 64.96 |
ADMA Biologics Inc is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing, and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The segments of the company are ADMA BioManufacturing, which generates maximum revenue, Plasma Collection Centres, and the corporate segment. The company sells plasma-derived intermediate fractions to certain customers, which are generated as part of its FDA-approved manufacturing process for IG and IVIG products. It also provides laboratory contracting services to certain customers and anticipates providing contract filling, labeling & packing services. The company derives maximum revenue from the United States.
PIMCO Corporate & Income Opportunity Fds operates as a closed-end management investment company. It seeks to maximize total return through a combination of current income and capital appreciation. The fund invests a majority of the total assets in a combination of corporate debt obligations of varying maturities, other corporate income-producing securities, and income-producing securities of non-corporate issuers, such as U.S. Government securities, municipal securities, and mortgage-backed and other asset-backed securities issued on a public or private basis.